Drugs / Cibisatamab
Cibisatamab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04826003 | Jul 2021 → Nov 2024 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03866239 | May 2019 → Mar 2024 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT02650713 | Jan 2016 → Jan 2020 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02324257 | Dec 2014 → Sep 2019 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cibisatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04826003 ↗ |
| Known as | Cea cd3 tcb | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298091 ↗ |
| Known as | RG-7802 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298091 ↗ |
| Known as | RO6958688 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03337698 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298091 ↗ |
| Route | Intravenous | “RO6958688 is given as an intravenous (IV) infusion” NCT02324257 ↗ |